Related Experiment Video
Updated: Jun 28, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Systematic analysis of outcomes evaluations applied to drug management programs
Carrie McAdam-Marx1, David T Schaaf, Anke-Peggy Holtorf
1Department of Pharmacotherapy, University of Utah, 421 Wakara Wy, Rm 208, Salt Lake City, UT 84108, USA. carrie.mcadam-marx@pharm.utah.edu
The American Journal of Managed Care
|November 15, 2008
Summary
Most studies on drug management programs fail to assess economic, clinical, and humanistic outcomes together. Improved evaluation measures are needed to truly gauge program quality and impact on health plans and patients.
Area of Science:
- Health Services Research
- Pharmacoeconomics
- Health Outcomes Research
Background:
- Drug management programs are increasingly evaluated for their impact on health plans and patients.
- Prior analyses have varied in their approach to measuring the effectiveness of these programs.
- Assessing program quality requires a comprehensive understanding of economic, clinical, and humanistic outcomes.
Purpose of the Study:
- To evaluate the effectiveness of prior analyses in measuring the quality of drug management programs.
- To determine how drug management programs impact health plans and patients.
- To identify gaps in the assessment of drug management program outcomes.
Main Methods:
- A systematic review of 77 US studies published between 1996 and 2007 was conducted.
- Studies evaluated drug management programs from various health plans, including managed care, indemnity insurance, Veterans Health Administration, and Medicaid.
- The review included studies assessing the impact of drug management tools and overall programs on economic, clinical, and humanistic outcomes.
Main Results:
- A total of 11 types of outcome endpoints were used across the 77 studies.
- Economic endpoints were the most common, included in 52 studies (68%), with 35 of these reporting only economic data.
- A smaller proportion of studies, 33 (43%), evaluated clinical or humanistic endpoints, and 17 of those also reported economic data.
Conclusions:
- Few studies have integrated economic, clinical, and humanistic outcomes when evaluating drug management programs.
- Current research efforts have limitations in assessing the overall quality and comprehensive impact of these programs.
- There is a critical need to improve the measures used for evaluating drug management programs to ensure desired effects on outcomes and costs.
Related Concept Videos
01:15Nursing Evaluation
The evaluation stage signals the end of the nursing process. The nurse gathers evaluative data to assess whether or not the patient has attained the expected results. Whereas the nurse collects data in the nursing assessment to identify the patient's health concerns, the evaluation stage data determines if the indicated health issues are resolved. Evaluative data collection includes two sections: the data acquired to evaluate patient outcomes and the time criteria for data collection.
Section...
Section...
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:12Analysis of Population Pharmacokinetic Data
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...